Bortezomib injection price in 2023

Bortezomib (Bortezomib) is an important drug used to treat certain types of cancer, especially malignant hematological tumors. Bortezomib belongs to the proteasome inhibitor class. This means that it affects protein degradation and intracellular metabolism by inhibiting proteasome activity in cells, thereby preventing the growth and proliferation of cancer cells.

Bortezomib is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of around 3,000 to 4,000 yuan. Please consult the local hospital pharmacy for specific prices and reimbursement policies. The cheaper ones abroad are mainly Indian generic drugs, which cost around 1,000 yuan and have basically the same ingredients as the domestic bortezomib drug.

Bortezomib is mainly used to treat malignant tumors such as multiple myeloma (Multiple Myeloma) and certain non-Hodgkin lymphomas (Non-Hodgkin Lymphoma). Multiple myeloma is a malignant plasma cell disease of the bone marrow, while non-Hodgkin lymphoma is a malignant tumor of the lymphatic system.

Bortezomib’s mechanism of action involves inhibiting the proteasome, a structure in cells responsible for protein degradation. By preventing protein degradation, bortezomib causes the accumulation of proteins in cancer cells, ultimately leading to apoptosis (cell death) of the cancer cells.

Bortezomib is usually given as an intravenous injection. Usage and dosage will vary based on the patient's specific condition and treatment regimen, often requiring physician supervision and regular treatment cycles.

Bortezomib may cause a range of side effects, including nausea, vomiting, diarrhea, peripheral neuropathy, thrombocytopenia, leukopenia, anemia, fever, renal damage, cardiovascular problems, liver damage, pulmonary toxicity, and elevated blood sugar. Therefore, patients need to be closely monitored and regularly evaluated.